将Nivolumab与化疗相结合可以提高存活率,减少Hodgkin淋巴瘤病人的副作用。 Combining nivolumab with chemotherapy improves survival rates and reduces side effects in advanced Hodgkin lymphoma patients.

最近的一项临床试验显示,将免疫疗法药物尼沃卢马布与标准化疗相结合,可显著提高晚期霍奇金淋巴瘤患者的生存率. A recent clinical trial revealed that combining the immunotherapy drug nivolumab with standard chemotherapy significantly enhances survival rates for patients with advanced Hodgkin lymphoma. 据该研究报告,尼沃卢马布治疗方案的两年无进展生存率为92%;而之前的标准治疗方案为83%. The study reported a two-year progression-free survival rate of 92% for the nivolumab regimen, compared to 83% for the previous standard treatment. 这一新办法的副作用也较少,使人们希望作为标准治疗办法予以采用。 This new approach also presents fewer side effects, leading to hopes for its adoption as a standard treatment option.